About AEterna Zentaris
Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women's health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others. The Company's principal product candidates are Zoptrex (zoptarelin doxorubicin) and Macrilen (macimorelin) in oncology and endocrinology. The Company focuses on its product candidates Zoptrex and Macrilen, which are in Phase III clinical development, and on a luteinizing hormone-releasing hormone (LHRH)-disorazol Z conjugate (AEZS-138), which is in pre-clinical development in oncology and is available for partnering. The Company's direct and indirect subsidiaries include AEZS GmbH, Zentaris IVF GmbH and Aeterna Zentaris, Inc.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: AEZS
- Previous Close: $3.35
- 50 Day Moving Average: $2.92
- 200 Day Moving Average: $3.47
- 52-Week Range: $2.35 - $5.59
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -3.38
- P/E Growth: 0.00
- Market Cap: $39.09M
- Outstanding Shares: 11,670,000
- Beta: 1.68
- Net Margins: -3,773.91%
- Return on Equity: -213.27%
- Return on Assets: -65.19%
Companies Related to AEterna Zentaris:
- Current Ratio: 3.98%
- Quick Ratio: 3.98%
Earnings History for AEterna Zentaris (NASDAQ:AEZS)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/21/2013||Q412||($0.31)||($0.29)||$7.96 million||$9.16 million||View||N/A|
|11/13/2012||Q312||($0.43)||($0.35)||$8.38 million||$7.10 million||View||N/A|
Earnings Estimates for AEterna Zentaris (NASDAQ:AEZS)
Current Year EPS Consensus Estimate: $-2.38 EPS
Next Year EPS Consensus Estimate: $-0.99 EPS
Dividend History for AEterna Zentaris (NASDAQ:AEZS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for AEterna Zentaris (NASDAQ:AEZS)
No insider trades for this company have been tracked by MarketBeat.com
Latest Headlines for AEterna Zentaris (NASDAQ:AEZS)
What is AEterna Zentaris' stock symbol?
AEterna Zentaris trades on the NASDAQ under the ticker symbol "AEZS."
Where is AEterna Zentaris' stock going? Where will AEterna Zentaris' stock price be in 2017?
3 analysts have issued 1 year price targets for AEterna Zentaris' stock. Their forecasts range from $6.00 to $10.00. On average, they anticipate AEterna Zentaris' share price to reach $7.83 in the next twelve months.
Who owns AEterna Zentaris stock?
AEterna Zentaris' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (2.64%).
Who sold AEterna Zentaris stock? Who is selling AEterna Zentaris stock?
AEterna Zentaris' stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.
How do I buy AEterna Zentaris stock?
Shares of AEterna Zentaris can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of AEterna Zentaris stock cost?
One share of AEterna Zentaris stock can currently be purchased for approximately $3.35.
AEterna Zentaris (NASDAQ:AEZS) Chart for Monday, February, 20, 2017
Institutional Ownership ChartEarnings History ChartDividend History Chart